Investigating blood disorders in ovarian cancer survivors
Official title: Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer
Funded at University of Washington · NIH-11078343 · Data updated 2026-11-12
This study is looking at how treatments for ovarian cancer might cause blood disorders later on, and it's for ovarian cancer survivors who want to help researchers find ways to prevent these issues and improve future treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $648,957 |
| NIH project number | 5R01CA272594-03 |
| Project ID | NIH-11078343 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women who have survived ovarian cancer and have undergone chemotherapy or maintenance therapy.
✕Less likely to help
Patients who have not been diagnosed with ovarian cancer or have not received chemotherapy are unlikely to benefit from this research.
What this research studies
This research focuses on understanding how chemotherapy and maintenance therapies for ovarian cancer can lead to long-term blood disorders, specifically therapy-related myeloid neoplasia (TMN). By enrolling 2000 ovarian cancer survivors, the study aims to identify early signs of clonal hematopoiesis, a pre-malignant condition that can precede TMN. The research will explore the natural progression of these blood disorders and seek to develop safer treatment strategies for ovarian cancer patients. Through this approach, the team hopes to provide insights that could lead to interventions that prevent the development of serious blood cancers.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment options for ovarian cancer patients and potentially prevent the development of life-threatening blood disorders.
How similar studies have gone: Previous research has shown that understanding clonal hematopoiesis can provide valuable insights into the progression of blood cancers, indicating that this approach has potential for success.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Swisher, Elizabeth Mary — University of Washington
- Study coordinator: Swisher, Elizabeth Mary
Related research
Other NIH-funded projects on the same topics.
-
Early blood changes and treatment-related leukemia risk after ovarian cancer
This project follows ovarian cancer survivors to look for early blood cell changes that can lead to treatment-related leukemia.
-
Treating bone marrow cancers linked to PARP inhibitor use in ovarian cancer survivors
Researchers are developing new drug strategies to treat aggressive bone marrow cancers that can occur after PARP inhibitor therapy in ovarian cancer survivors.
-
Improving treatment for blood cancers in ovarian cancer survivors
This study is looking for better treatment options for ovarian cancer patients who develop serious blood disorders after using certain medications, especially those with a specific gene mutation that makes standard treatments less effective, so they can live longer and feel better.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.